We have 3 of 28 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Despite the established benefit of adjuvant trastuzumab emtansine (T-DM1) over trastuzumab in HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant chemotherapy plus HER2-targeted therapy, comparison of efficacy between T-DM1 and dual HER2 blockade (trastuzumab plus pertuzumab, HP) remai...
A clinical model incorporating age (≥65 years), T stage (T3/T4), N stage (N2/N3), and chemotherapy (no) was developed to predict inferior OS in early-stage MedBC.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
